Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Article info

In Press

Keywords

• CD19 CAR T Cells
• FDA-approved therapies
• Immunotherapy
• Advancement in Cancer Therapy.
• Bispecific Antibody therapy
• Immune Check Point Inhibitors
• CAR T cell therapy

Abstract

Cancer treatment is witnessing significant advancements with two notable therapies: Chimeric Antigen Receptor (CAR) T cell therapy and Bispecific antibody therapy. These therapies represent a shift towards more personalized cancer care. CAR T cell therapy modifies a patient's immune cells, known as T cells, to target and destroy cancer cells. This method has been effective in treating blood cancers like leukemia. However, it faces challenges when dealing with solid tumors, such as those in breast or lung cancer, and can sometimes cause severe side effects. Additionally, the complex environment of tumors poses a significant hurdle. Bispecific antibody (BsAb) therapy, in contrast, uses specially designed antibodies. These antibodies can attach to both cancer cells and immune cells, aiding the immune system in identifying and eliminating cancer cells. This approach is effective against both solid and liquid cancers but requires further refinement to enhance its effectiveness and safety. While both therapies have achieved remarkable successes, they also confront distinct challenges. CAR T cell therapy excels in treating blood cancers but struggles with solid tumors and managing side effects. Bispecific antibody therapy shows promise but needs more development to optimize its benefits. These therapies are at the forefront of a movement towards treatments that are more tailored to individual patients. Ongoing research aims to overcome their limitations, making them safer and more effective for a broader range of cancers. This review underscores the progress and obstacles of these innovative therapies. It highlights the ongoing pursuit of more precise, effective treatments that could revolutionize the future of cancer care.

معلومات المقال

قيد النشر

الكلمات الإفتتاحية

• CD19 CAR T Cells
• FDA-approved therapies
• Immunotherapy
• Advancement in Cancer Therapy.
• Bispecific Antibody therapy
• Immune Check Point Inhibitors
• CAR T cell therapy

الملخص

Cancer treatment is witnessing significant advancements with two notable therapies: Chimeric Antigen Receptor (CAR) T cell therapy and Bispecific antibody therapy. These therapies represent a shift towards more personalized cancer care. CAR T cell therapy modifies a patient's immune cells, known as T cells, to target and destroy cancer cells. This method has been effective in treating blood cancers like leukemia. However, it faces challenges when dealing with solid tumors, such as those in breast or lung cancer, and can sometimes cause severe side effects. Additionally, the complex environment of tumors poses a significant hurdle. Bispecific antibody (BsAb) therapy, in contrast, uses specially designed antibodies. These antibodies can attach to both cancer cells and immune cells, aiding the immune system in identifying and eliminating cancer cells. This approach is effective against both solid and liquid cancers but requires further refinement to enhance its effectiveness and safety. While both therapies have achieved remarkable successes, they also confront distinct challenges. CAR T cell therapy excels in treating blood cancers but struggles with solid tumors and managing side effects. Bispecific antibody therapy shows promise but needs more development to optimize its benefits. These therapies are at the forefront of a movement towards treatments that are more tailored to individual patients. Ongoing research aims to overcome their limitations, making them safer and more effective for a broader range of cancers. This review underscores the progress and obstacles of these innovative therapies. It highlights the ongoing pursuit of more precise, effective treatments that could revolutionize the future of cancer care.